Research Article| Volume 32, ISSUE 2, P275-292, February 2010

Download started.


Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: Interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets

      This paper is only available as a PDF. To read, Please Download here.


      Background: The safety and efficacy of paliperidone extended-release tablets (paliperidone ER) in patients with acute symptoms of schizophrenia have been described in 3 randomized, double-blind, 6-week, placebo-controlled, fixed-dose, Phase III clinical trials. The validity and reliability of the Personal and Social Performance (PSP) scale, both in patients with acute symptoms of schizophrenia and those with stabilized symptoms, have also been reported.
      Objective: The aim of this work was to estimate the treatment benefit of paliperidone ER compared with placebo in terms of improvements in personal and social functioning as measured by the PSP scale in 3 controlled clinical trials.
      Methods: Data were derived from 3 paliperidone ER multicenter Phase III pivotal studies of patients with acute symptoms of schizophrenia. Each study included a randomized, double-blind, placebo- and active-controlled, parallel-group, 6-week treatment period with an open-label extension of paliperidone ER treatment. Patients were randomized to receive paliperidone ER, olanzapine 10 mg, or placebo once daily. Paliperidone ER doses were 3, 9, and 15 mg/d in 1 study; 6, 9, and 12 mg/d in another; and 6 and 12 mg/d in the third. Collectively, 1306 intent-to-treat patients received placebo or paliperidone ER in these 3 trials. Most (61.7%) were white; 21.6% were black, 8.8% were Asian, and 7.9% were of another race. The mean age ranged from 36.3 to 39.4 years across treatment groups. Multiple analyses were applied to PSP data (for which higher scores indicate better personal and social functioning) from these paliperidone ER studies: between-group minimum important difference (MID) estimates; responder analyses; between-group cumulative frequency comparisons of PSP change from baseline to end point; and number-needed-to-treat (NNT) estimates.
      Results: Standardized differences and effect sizes between paliperidone ER and placebo in PSP mean change from baseline to end point ranged from 0.52 to 0.85 for all paliperidone ER doses. Observed between-group differences (paliperidone ER minus placebo) in PSP mean change from baseline to end point exceeded the between-group MID of 7 points at all paliperidone ER doses. The percentage of patients achieving at least one 10-point category improvement in the PSP was higher with all paliperidone ER doses (range, 49.6%–63.6%) than placebo (33.1%) (P < 0.005). Across the distribution of all possible PSP scores, the percentage of patients achieving any level of change appeared to be greater for paliperidone ER than for placebo at all doses. Derived NNTs for improved personal and social functioning based on paliperidone ER trials ranged from 3.3 to 6.1. The improvement in personal and social functioning achieved by patients receiving paliperidone ER during the double-blind studies was maintained throughout the 52-week, open-label extension studies, as assessed using multiple definitions of response; subjects in the placebo arm during doubleblind treatment appeared to achieve and maintain improved functioning when switched to paliperidone ER for the extension studies.
      Conclusion: These results suggest that paliperidone ER had a meaningful treatment benefit with respect to improving personal and social functioning in these patients with acute symptoms of schizophrenia.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Schizophrenia and other psychotic disorders.
        in: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC2000: 297-313
        • Johannessen JO
        Review: Lifetime prevalence of schizophrenia and related disorders is about 5.5 per 1000, but there is significant variation between regions.
        Evid Based Ment Health. 2003; 6: 74
        • Nasrallah HA
        • Lasser R
        Improving patient outcomes in schizophrenia: Achieving remission.
        J Psychopharmacol. 2006; 20: 57-61
        • Taylor M
        • Chaudhry I
        • Cross M
        • et al.
        • Relapse Prevention in Schizophrenia Consensus Group
        Towards consensus in the long-term management of relapse prevention in schizophrenia.
        Hum Psychopharmacol. 2005; 20: 175-181
        • Davidson M
        • Emsley R
        • Kramer M
        • et al.
        Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study [published correction appears in Schizophr Res. 2007;96:273–274].
        Schizophr Res. 2007; 93: 117-130
        • Kane J
        • Kramer M
        • Ford L
        • et al.
        Treatment of schizophrenia with paliperidone extended release: A 6-week placebocontrolled trial.
        Schizophr Res. 2007; 90: 147-161
        • Marder SR
        • Kramer M
        • Ford L
        • et al.
        Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study.
        Biol Psychiatry. 2007; 62: 1363-1370
        • Morosini PL
        • Magliano L
        • Brambilla L
        • et al.
        Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning.
        Acta Psychiatr Scand. 2000; 101: 323-329
        • Nasrallah H
        • Morosini PL
        • Gagnon DD
        Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
        Psychiatry Res. 2008; 161: 213-224
        • Patrick DL
        • Burns T
        • Morosini PL
        • et al.
        Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
        Curr Med Res Opin. 2009; 25: 325-338
        • Juckel G
        • Schaub D
        • Fuchs N
        • et al.
        Validation of the Personal and Social Performance (PSP) scale in a German sample of acutely ill patients with schizophrenia.
        Schizophr Res. 2008; 104: 287-293
        • Food and Drug Administration (FDA)
        Guidance for Industry: Patient Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.
        (Accessed December 18, 2009)
      2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines on Good Clinical Practice.
        (Accessed February 5, 2010)
        • Meltzer HY
        • Bobo WV
        • Nuamah IF
        • et al.
        Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies.
        J Clin Psychiatry. 2008; 69: 817-829
        • Emsley R
        • Berwaerts J
        • Eerdekens M
        • et al.
        Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week open-label studies.
        Int Clin Psychopharmacol. 2008; 23: 343-356
        • Kay SR
        • Fiszbein A
        • Opler LA
        The Positive And Negative Syndrome Scale (PANSS) for schizophrenia.
        Schizophr Bull. 1987; 13: 261-276
        • Guy W
        Clinical Global Impressions.
        in: ECDEU Assessment Manual for Psychopharmacology. National Institutes of Mental Health, Rockville, Md1976: 218-222
        • Norman GR
        • Wyrwich KW
        • Patrick DL
        The mathematical relationship among different forms of responsiveness coefficients.
        Qual Life Res. 2007; 16: 815-822
        • Hedges LV
        • Olkin I
        Statistical Methods for Meta-Analysis. Academic Press, Orlando, Fla1985
        • Cohen J
        Statistical Power Analysis for the Behavioral Sciences. 2nd ed. L. Erlbaum Associates, Hillsdale, NJ1988
        • Guyatt GH
        • Osoba D
        • Wu AW
        • et al.
        • Clinical Significance Consensus Meeting Group
        Methods to explain the clinical significance of health status measures.
        Mayo Clin Proc. 2002; 77: 371-383
        • Lydick E
        • Epstein RS
        Interpretation of quality of life changes.
        Qual Life Res. 1993; 2: 221-226
        • Lydick E
        Approaches to the interpretation of quality-of-life scales.
        Med Care. 2000; 38: II180-II183
        • Sloan JA
        • Dueck A
        Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials.
        J Biopharm Stat. 2004; 14: 73-96
        • Wyrwich KW
        Minimal important difference thresholds and the standard error of measurement: Is there a connection?.
        J Biopharm Stat. 2004; 14: 97-110
        • Hays RD
        • Brodsky M
        • Johnston MF
        • et al.
        Evaluating the statistical significance of health-related quality-of-life change in individual patients.
        Eval Health Prof. 2005; 28: 160-171
        • Wyrwich KW
        • Bullinger M
        • Aaronson N
        • et al.
        • Clinical Significance Consensus Meeting Group
        Estimating clinically significant differences in quality of life outcomes.
        Qual Life Res. 2005; 14: 285-295
        • Patrick DL
        • Burke LB
        • Powers JH
        • et al.
        Patient-reported outcomes to support medical product labeling claims: FDA perspective.
        Value Health. 2007; 10: S125-S137
        • Laupacis A
        • Sackett DL
        • Roberts RS
        An assessment of clinically useful measures of the consequences of treatment.
        N Engl J Med. 1988; 318: 1728-1733
        • Kramer M
        • Simpson G
        • Maciulis V
        • et al.
        Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, doubleblind, placebo-controlled study [published correction appears in J Clin Psychopharmacol. 2007;27:258].
        J Clin Psychopharmacol. 2007; 27: 6-14
        • Tzimos A
        • Samokhvalov V
        • Kramer M
        • et al.
        Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: A double-blind, placebo-controlled study with six-month open-label extension.
        Am J Geriatr Psychiatry. 2008; 16: 31-43
        • Pinson L
        • Gray GE
        Psychopharmacology: Number needed to treat: An underused measure of treatment effect.
        Psychiatr Serv. 2003; 54: 145-146
        • Pinson L
        • Gray GE
        Psychopharmacology: Number needed to treat: An underused measure of treatment effect.
        Psychiatr Serv. 2003; 54: 154
        • Potkin SG
        • Saha AR
        • Kujawa MJ
        • et al.
        Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
        Arch Gen Psychiatry. 2003; 60: 681-690
        • Beasley Jr, CM
        • Tollefson G
        • Tran P
        • et al.
        Olanzapine versus placebo and haloperidol: Acute phase results of the North American doubleblind olanzapine trial.
        Neuropsycho-pharmacology. 1996; 14: 111-123
        • Borison RL
        • Arvanitis LA
        • Miller BG
        • US SEROQUEL Study Group
        ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia.
        J Clin Psychopharmacol. 1996; 16: 158-169
        • Keck Jr, P
        • Buffenstein A
        • Ferguson J
        • et al.
        Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial.
        Psychopharmacology (Berl). 1998; 140: 173-184
        • Oken MM
        • Creech RH
        • Tormey DC
        • et al.
        Toxicity and response criteria of the Eastern Cooperative Oncology Group.
        Am J Clin Oncol. 1982; 5: 649-655
        • Schag CC
        • Heinrich RL
        • Ganz PA
        Karnofsky performance status revisited: Reliability, validity, and guidelines.
        J Clin Oncol. 1984; 2: 187-193
      3. The Criteria Committee of the New York Heart Association.
        in: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little, Brown & Co, Boston, Mass1994: 253-256
        • Furukawa TA
        • Takeuchi H
        • Hiroe T
        • et al.
        Symptomatic recovery and social functioning in major depression.
        Acta Psychiatr Scand. 2001; 103: 257-261
        • Priebe S
        • Watzke S
        • Hansson L
        • Burns T
        Objective social outcomes index (SIX): A method to summarise objective indicators of social outcomes in mental health care.
        Acta Psychiatr Scand. 2008; 118: 57-63